Adjuvanted leptospiral vaccines: Challenges and future development of new leptospirosis vaccines.

  title={Adjuvanted leptospiral vaccines: Challenges and future development of new leptospirosis vaccines.},
  author={Aline F Teixeira and Luis G V Fernandes and Maria F. Cavenague and Maria Beatriz Takahashi and Jademilson C Santos and Felipe Jos{\'e} Passalia and Brenda Bevilaqua Daroz and Leandro Toshio Kochi and M{\^o}nica Larucci Vieira and Ana Lucia Tabet Oller Nascimento},
Leptospirosis is a neglected infectious disease of global importance. Vaccination is the most viable strategy for the control of leptospirosis, but in spite of efforts for the development of an effective vaccine against the disease, few advances have been made, and to date, bacterin is the only option for prevention of leptospirosis. Bacterins are formulations based on inactivated leptospires that present a series of drawbacks, such as serovar-dependence and short-term immunity. Therefore… 
New strategies for Leptospira vaccine development based on LPS removal
The results showed that bivalent vaccines with reduced LPS may be an interesting strategy for protection against heterologous virulent serovars, and the low LPS vaccines are specially promising due to the expected lower reatogenicity.
An overview of human leptospirosis vaccine design and future perspectives
This review covers the most promising vaccine candidates that induced significant, reproducible, protection and how advances in the field of bioinformatics has led to the discovery of hundreds of novel protein targets.
Immunoprotective Activity Induced by Leptospiral Outer Membrane Proteins in Hamster Model of Acute Leptospirosis
These are the first proteins involved with human complement components with the capacity to protect against virulent challenge and to eliminate the bacteria from the host.
Poly(diaminosulfide) Microparticle-Based Vaccine for Delivery of Leptospiral Antigens.
It can be concluded that L203-PNSN is a novel first-in-class microparticle-based Leptospira vaccine that represents a powerful platform with the potential to serve as a prophylactic vaccine against leptospiral infection in cattle.
Leptospira infection in people in the city of Durango, Mexico: a cross sectional study
Multivariate analysis showed that Leptospira seropositivity was associated with professional occupation, alcohol consumption, ill clinical status, memory impairment and a history of surgery, which was higher than those previously reported in Mexican studies.
Halloysite nanotubes (HNTs) are hollow clay nanotubes in the nanometer size range, made up of double-layered aluminum silicate mineral layers. HNTs represent an extremely versatile, safe, and


LigB subunit vaccine confers sterile immunity against challenge in the hamster model of leptospirosis
Evaluated a subunit vaccine preparation, based on a conserved region of the leptospiral immunoglobulin-like B protein (LigB(131–645)) and aluminium hydroxide (AH), in the hamster model of leptonospirosis, and suggest that LigB (131-645) is a vaccine candidate against leptosphererosis with potential ramifications to public and veterinary health.
Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis.
The data of the present study suggest that smegmosomes will serve well as a promising delivery vehicle/adjuvant system that can induce both Th1 and Th2 type immune responses and provide a novel tool in development of improved vaccines for leptospirosis and other infectious diseases.
Antigenic potential of a recombinant polyvalent DNA vaccine against pathogenic leptospiral infection.
The leptospiral multi-epitope chimeric DNA vaccine can serve as a potentially effective and safe vaccine against infection with different pathogenic Leptospira species and significantly reduced renal colonization following in vivo challenge.
Chimeric epitope vaccine against Leptospira interrogans infection and induced specific immunity in guinea pigs
The multi-epitope chimeric r4R protein is a promising antigen for the development of a universal cross-reactive vaccine against leptospirosis.
Subunit Approach to Evaluation of the Immune Protective Potential of Leptospiral Antigens
Evaluated 27 recombinant antigens to determine their potential to induce an immune response protective against leptospirosis in the hamster model found only recombinant proteins LIC10325 and LIC13059 induced significant protection against mortality.
Xanthan Gum as an Adjuvant in a Subunit Vaccine Preparation against Leptospirosis
Xanthan gum is a high molecular weight extracellular polysaccharide produced by fermentation of Xanthomonas spp.
Evaluation of the Leptospira interrogans Outer Membrane Protein OmpL37 as a Vaccine Candidate
OmpL37, a potentially surface-exposed antigen that has the highest elastin-binding ability described to date, suggests that it plays an important role in host colonization, and prime-boost, DNA and subunit vaccine strategies were tested in the hamster model of lethal leptospirosis, but none of the OmpL 37 formulations or vaccination strategies induced protective immunity.
Protection against Lethal Leptospirosis after Vaccination with LipL32 Coupled or Coadministered with the B Subunit of Escherichia coli Heat-Labile Enterotoxin
This is the first report of a protective immune response afforded by a subunit vaccine using LipL32 and represents an important contribution toward the development of improved leptospirosis vaccines.
A Prime-Boost Strategy Using the Novel Vaccine Candidate, LemA, Protects Hamsters against Leptospirosis
Characterization of the immune response found that the strongest antibody response was stimulated by the subunit vaccine preparation, followed by the prime-boost strategy, and the DNA vaccine failed to elicit an antibody response in immunized hamsters.
LemA and Erp Y-like recombinant proteins from Leptospira interrogans protect hamsters from challenge using AddaVax™ as adjuvant.
Evaluated proteins in formulations containing the adjuvant AddaVax suggest that LemA and Erp Y-like proteins act as adhesins and are able to protect against mortality, but not against tissue lesions.